Life Scientist > Biotechnology

Pharmaxis to reduce board size to four

20 September, 2013 by Dylan Bushell-Embling

Two Pharmaxis (ASX:PXS) independent directors have retired and the newly-restructured company is using the opportunity to shave down its board size.


Freehills adds new partner

20 September, 2013

Freehills Patent Attorneys has appointed another a partner in their pharmaceutical and biotechnology practice.


Be a part of the first Australian world brain mapping congress: call for papers and registrations open

19 September, 2013

For the first time in Australia, all disciplines involved in brain mapping and therapies will gather at the one conference when the 11th Annual World Congress of the Society for Brain Mapping and Therapeutics (SBMT Congress) comes to Sydney early next year.


BioDiem's BDM-I presented at antimicrobial meet

19 September, 2013 by Dylan Bushell-Embling

A poster presentation detailing the activity of BioDiem's (ASX:BDM-I) animicrobial BDM-I in nearly 70 fungal infections has been presented at an interscience conference.


Calzada files for US approval for NovoSorb in TNP

18 September, 2013 by Dylan Bushell-Embling

Calzada (ASX:CZD) has submitted an application with the US FDA for its NovoSorb wound dressings in procedures involving topical negative pressure (TNP).


SMART Arm wins CA grant for limb rehab device

18 September, 2013 by Dylan Bushell-Embling

Start-up SMART Arm will receive a grant worth $200K to help commercialise its eponymous upper limb rehabilitation device for stroke victims.


AusBiotech welcomes new Coalition ministry

17 September, 2013

AusBiotech has welcomed the new Coalition ministry; in particular, the new Minister for Industry, Ian Macfarlane, who is returning to the portfolio he held from 2001 to 2007 when he was the Minister for Industry (Tourism and Resources).


Last call for nominations to the board of AusBiotech and 2013 Industry Excellence Awards

12 September, 2013

Nominations will close shortly for candidates to nominate for the AusBiotech board of directors and for the Janssen 2013 Industry Excellence Awards, which recognise those who have made a significant contribution to the biotechnology industry.


SYNthesis med chem opens UK lab

10 September, 2013 by Dylan Bushell-Embling

Australia-based CRO SYNthesis med chem has opened a UK facility to support its existing labs in Melbourne and Shanghai.


Australia’s first Tech Transfer Summit concludes with call for greater support for commercialisation

10 September, 2013

TTS Australia 2013 brought together 150 leading tech transfer professionals from Australia and the international community to help build expertise and relationships that enable successful tech transfer - that which results in the translation of research into products to benefit our community.


Tailoring cancer drug dosage

10 September, 2013

Scientists from Flinders University are collaborating with clinicians from Flinders Medical Centre to make a class of cancer drugs more effective by allowing patients to receive the dose that is best for them.


QRxPharma, FDA to discuss MoxDuo setback in October

09 September, 2013 by Dylan Bushell-Embling

QRxPharma (ASX:QRX) will meet with the US FDA in October to discuss the issues raised in the latest Complete Response Letter for dual-opioid drug MoxDuo.


pSivida to present at two US investor conferences

09 September, 2013 by Dylan Bushell-Embling

pSivida (ASX:PVA) will this week make presentations at the Rodman & Renshaw Annual Global Investment Conference and the Stifel Nicolaus Healthcare Conference.


iSonea wins CE Mark for AirSonea

09 September, 2013 by Dylan Bushell-Embling

iSonea (ASX:ISN) has gained the certification required for a CE Mark for its AirSonea wheeze monitoring tool, paving the way for an EU launch following its debuts in Australia and the US.


ACIP releases options paper on innovation patents

05 September, 2013

The Advisory Council on Intellectual Property (ACIP) has just released an Options Paper for its Review of the Innovation Patent System. ACIP is seeking stakeholder comments on policy issues that address the full range of possibilities for the innovation patent system.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd